CTA gene of interest % Tissue Expression(number of positive samples/total samples tested) Matched normal tissue tested? % Cell Line Expression
(number of positive samples/total samples tested)
% Serological detection
(positive detection e.g. with ELISA/number of individuals tested)
Comment
AKAP3 (5/6) 83.3% [109] No (3/10) 30% [109]    
BCP-20(FBXO39) (22/57) 38.6% [66] No (2/7) 28.6% [32]   Expressed weakly in normal ovary, placenta, lung and prostate
BCP-33 (LOC374973) (12/57) 21.1% [66] No     Expressed weakly in normal pancreas
BCP-41(TTLL2) (17/57) 29.8% [66] No     Weak expression in various normal tissues
BJ-HCC-20 (3/18) 16.7% [110] Yes      
BORIS (8/10) 80% [111] No (3/4) 75% [33]    
CAGE (35/47) 74.4% [55,64] Yes (2/4) 50% [112] (7/74) 9.9% [25,27] Expression seen in some normal colonic tissue (see main text for discussion)
CCDC62-2 (5/40) 12.5% [113] No   (2/11) 18.2% [113]  
CT16 (1/9) 11.1% [114] No     CT16 has homology with GAGEfamily
CT45 (36/250) 14.4% [60] Yes      
cTAGE-1 (6/39) 15.4% [100] No See comment   Cell line and tissue expression frequency combined (31 tumours and 8 CRC cell lines used)
cTAGE-5A (13/39) 33.3% [100] No See comment   See comment for cTAGE-1
CTp11 (2/9) 22.2% [115] No      
DBPC (CONTRIN) (9/10) 90% [116] No     Protein production assessed using IHC – no PCR used
FATE(FATE-1, BCP-55) (3/14) 21.4% [117] Yes (0/2) 0% [23]    
FAM46D (4*/18) 22.2% [118] No   (0/18) 0% [118] *Number positive estimated from percentage displayed
GASZ (4*/18) 22.2% [118] No   (0/18) 0% [118] *Number positive estimated from percentage displayed
HAGE (46/288) 16.0% [60,115,119] Yes, except [115]      
IGSF11 (6/11) 54.5% [120] No      
KP-CoT-23 (CCDC83) [122]     (26/37) 70.3% [121]  
LAGE-1 (68/503) 13.5% [55,60,61,122] Yes      
LDHC (3/20) 15% [50] No      
LEMD1 (17/18) 50.4% [123] Yes     Used matched normal tissue but data not presented
MAGE-1 (MAGE-A1) (63/484) 13.0% [55,60,61,65,124] Yes, except [125] (7/12) 58.3% [58,65] (0/25) 0% [125] [58] – also tested CRC tissue but incomplete data provided
MAGE-2 (MAGE-A2) (62/338) 18.3% [55,60,65] Yes (6/17) 35.3% [58,65,85]   [58] – also tested CRC tissue but incomplete data provided
MAGE-3 (MAGE-A3) (118/535) 22.1% [55,60,61,65,67,126] Yes, except [126] (7/24) 29.2% [65,127] (0/25) 0% [125] Note: MAGE-3 has extensive homology to MAGE-6
MAGE-4 (MAGE-A4) (79/419) 18.9% [60,61,67] Yes (4/17) 23.5% [58,65,85]   [58] – also tested CRC tissue but incomplete data provided
MAGE-A5 (17/250) 6.8% [60] Yes      
MAGE-A6 (69/250) 27.6% [60] Yes (2/5) 40% [85]    
MAGE-A10 (1/48) 2.1% [67] Yes      
MAGE-A12 47%* or more [57] (0/34) 0% [55] Yes (4/4) 100% [58]   *See main text for discussion. [58] – also tested CRC tissue but incomplete data provided
MAGE-C1 (CT7) (4/305) 1.3% [55,60,93,127] Yes, except [92]     [128] – Identified by IHC in one sample but none by PCR
MAGE-C2 (CT10) (22/381) 5.8% [60,61,128] Yes, except [128] (1/2) 50% [50]   CT10/MAGE-C2 shows extensive homology to CT7/MAGE-C1
NXF2 (2/18) 11.1% [90] No      
NY-ESO-1 (34/567) 6.0% [55,60,61,67,122,130] Yes, except [129]   (1/107) 0.9% [61,125]  
OY-TES-1 (2/13) 15.4% [130] No   (6/58) 10.3% [130]  
PAGE-4 (74/250) 29.6% [60] Yes      
PASD1 (8*/18) 38.9% [118] No   (0/18) 0% [118] *Number positive estimated from percentage displayed
POTE (7/7) 100% [68] No     No normal colon tissue analysed in this study
SCP-1 (14/403) 3.5% [60,61,132] Yes, except [131]      
SPAG9 (58/78) 74.3% [90] Yes (2/2) 100% [91] (38/54) 70.4% [91] Matched normal tissue obtained in 26 of 78 samples
SPANX (15/250) 6% [60] Yes      
SSX-1 (10/561) 1.8% [55,60,61,122,132] Yes, except [131]      
SSX-2 (37/641) 5.8% [55,60,61,67,122,132,132] Yes, except [132,133]   (2/99) <2.0%*[73,125] *Unclear how many sera samples tested in [133]
SSX-4 (50/561) 8.9% [55,60,61,122,132] Yes, except [132]      
SSX-5 (1/58) 1.7% [132] No      
TEKT5 (5/10) 50% [134] No (4/44) 9.1% [134]    
TPTE (13/264) 4.9% [60,117] Yes (0/2) 0% [117]    
TRAG-3 (6/92) 6.5% [135,136] Yes but see comment (3/11) 27.3% [135]   [136] – demonstrated weak expression in one adjacent normal tissue sample and also included two purchased cDNA CRCs not matched.
TSGA10 (1/20) 5% [137] No   0% [137]  
TSP50 (85*/95) 89.5% [92] No (7/7) 100% [92]   *Assessed by IHC in CRC tissue. Weak positivity also in 60% of normal controls.
ZNF165 (6/14) 42.9% [138] Yes      
Abbreviations: IHC – Immunohistochemistry, PCR – Polymerase Chain Reaction, * – see comment on same row
Table 1: CTA genes that have been demonstrated to have expression in CRC tissue.